> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Updates Compliance Program for Biologic Drug Manufacturers
- URL: https://www.fdaweb.com/fda-updates-compliance-program-for-biologic-drug-manufacturers/
- Published: 2026-04-15T12:00:00.000Z
- Updated: 2026-09-14T13:37:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5160991

FDA has issued an updated [compliance program](https://www.fda.gov/media/191983/download?attachment&ref=fdaweb.com) that standardizes how inspectors evaluate manufacturing facilities tied to biologic drug applications, reinforcing a risk-based approach to oversight while tightening timelines for communication and follow-up.

The program, released 4/14 and set to take effect 5/14, outlines procedures for pre-license inspections (PLIs) and preapproval inspections (PAIs) conducted by CDER. These inspections are critical steps in determining whether facilities producing biologic therapies — such as protein-based drugs — meet regulatory standards required for approval.

The updated program emphasizes a risk-based inspection model, allowing the FDA to determine when and how to inspect facilities based on factors such as manufacturing complexity, compliance history, and product risk. The agency also highlighted the use of “alternative tools,” including remote interactive evaluations, to supplement or, in some cases, replace on-site inspections.

If inspections uncover deficiencies limited to a single product under review, broader enforcement actions may be avoided. However, systemic issues — such as data integrity problems — must be escalated to compliance officials and could trigger wider regulatory scrutiny, according to the program guide

The compliance program underscores two primary inspection objectives: verifying adherence to current good manufacturing practice (CGMP) requirements and auditing data integrity. These areas are central to ensuring that biologic products are “safe, pure, and potent,” as required under federal law. Facilities failing to meet standards may face a “withhold” recommendation, delaying or blocking product approval until corrective actions are verified, it says.

The FDA also reiterated the importance of internationally recognized manufacturing guidelines, including those from the International Council for Harmonization. Guidance such as ICH Q7 (for active pharmaceutical ingredients) and ICH Q12 (for lifecycle management) are referenced as key frameworks for compliance and efficient postapproval change management.